EAU 2026 | Optimizing mitomycin C maintenance for intermediate-risk NMIBC

Roberto Contieri • 15 Mar 2026

EAU 2026

Roberto Contieri, MD, Humanitas University, Rozzano, Italy, discusses the use of adjuvant intravesical chemotherapy in intermediate non-muscle invasive bladder cancer (NMIBC) highlighting the lack of strict guidelines on maintenance schedules. Dr Contieri presents findings from a retrospective database analysis in Italy, which suggest that patients who receive at least six monthly instillations of maintenance therapy have improved recurrence-free survival rates. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.